Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Assets (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Assets for 7 consecutive years, with $1.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, Assets rose 34.19% to $1.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.5 billion, a 34.19% increase, with the full-year FY2025 number at $1.5 billion, up 34.19% from a year prior.
  • Assets was $1.5 billion for Q4 2025 at Beam Therapeutics, up from $1.3 billion in the prior quarter.
  • In the past five years, Assets ranged from a high of $1.5 billion in Q4 2025 to a low of $693.2 million in Q1 2021.
  • A 5-year average of $1.3 billion and a median of $1.3 billion in 2022 define the central range for Assets.
  • Peak YoY movement for Assets: surged 315.62% in 2021, then dropped 24.38% in 2024.
  • Beam Therapeutics' Assets stood at $1.5 billion in 2021, then decreased by 9.0% to $1.3 billion in 2022, then grew by 8.79% to $1.5 billion in 2023, then decreased by 24.38% to $1.1 billion in 2024, then skyrocketed by 34.19% to $1.5 billion in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Assets are $1.5 billion (Q4 2025), $1.3 billion (Q3 2025), and $1.4 billion (Q2 2025).